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Abstract
The yeast Saccharomyces cerevisiae is a well-established model system for understanding
fundamental cellular processes relevant to higher eukaryotic organisms. Less known is its value for
virus research, an area in which Saccharomyces cerevisiae has proven to be very fruitful as well. The
present review will discuss the main achievements of yeast-based studies in basic and applied virus
research. These include the analysis of the function of individual proteins from important
pathogenic viruses, the elucidation of key processes in viral replication through the development
of systems that allow the replication of higher eukayotic viruses in yeast, and the use of yeast in
antiviral drug development and vaccine production.
Review
The yeast Saccahromyces cerevisiae has been successfully
used for many years as a model organism to unravel bio-
logical processes in higher eukaryotes. Because it is easy to
grow and to manipulate genetically it has been always at
the forefront of technical advances. For example, S. cerevi-
siae was the first eukayotic organism whose genome was
sequenced. The complete yeast genome is known since
1996 and comprises 6000 genes, from which more than
60% have an assigned function. Remarkably, comparative
genomic analysis have shown that approximately 40% of
yeast genes share conserved amino acid sequences with at
least one known or predicted human protein [1]. Moreo-
ver, 30% of human genes with a recognized involvement
in human diseases have orthologs in yeast [2]. Due to this
notable gene homology and the high conservation of fun-
damental biochemical pathways, studies in yeast have
been essential for understanding fundamental cellular
processes such as mRNA translation and degradation
[3,4], DNA repair mechanisms [5] and the cell cycle [6].
Many of these studies were carried out using classical
genetic tools in which a few number of genes can be ana-
lyzed at a time. However new technological platforms and
tools have been recently created that allow large-scale
functional analysis in yeast.
These platforms and tools are commercially available and
comprise (i) gene-deletion mutant collections that
include ~6000 heterozygous diploid strains, each of
which contains a deletion of a single copy of one specific
gene, and ~5000 homozygous diploid and haploid strains
in which each of the non-essential yeast genes is deleted
[7,8], (ii) essential gene mutant collections that include
an extensive set of promoter-shutoff strains in which the
essential genes are placed under the control of a tetracy-
cline(tet)-repressible promoter [9], and a set of heat
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inducible shutoff strains to generate ts alleles of essential
genes [10]. Both systems allow the study of the ~1000
essential genes in a homozygous background; (iii) gene-
expression libraries that include plasmids in which each
yeast gene is cloned under the control of the galactose-
inducible GAL1 promoter. An additional set of plasmids
have been created in which the yeast proteins are fused
with different tags such as the Flag epitope, the glutath-
ione S. transferase (GST) or the histidine 6 repeat (his6)
[11-14]; (iv) DNA microarrays have been created that
allow to assess the level of expression of thousands of
yeast genes in parallel [15,16], and (v) protein chips con-
taining approximately 5800 yeast proteins fused to GST-
his6 [14]. All these tools have opened new avenues in
medical research in which systematic genome-wide
screenings can be used to characterize disease-related
molecular events and to discover novel medical com-
pounds [17-19].
Viruses remain a major thread for human and animal
health as well as in agriculture. Nowadays, there is still no
vaccine or curative therapy available for main virus path-
ogens such as the Human immunodeficiency virus (HIV) and
the Hepatitis C virus (HCV). In this respect, a detailed
understanding of the biology of pathogenic viruses
together with new and systematic screening tools for
novel antiviral compounds will be most helpful. As for the
cellular biology studies mentioned above, virologist have
turned to the use of yeast as a model system to approach
fundamental issues in basic and applied research of
higher eukaryotic viruses. These studies have exploited the
classical yeast genetics and also the recent yeast technolog-
ical platforms that allow to apply a system biology
approach to fundamental questions in virus biology. The
present review will discuss first the expression of individ-
ual proteins from important pathogenic viruses in yeast to
elucidate their function. The vast literature on the yeast
two-hybrid system as a method to explore protein-protein
interactions however is not a subject of this review. Sec-
ond, the establishment of yeast/virus systems that allow
the replication of higher eukayotic viruses in yeast. These
systems have made groundbreaking contributions in the
dissection of the life cycle of viruses and the host factors
involved. Finally, the third and fourth sections will focus
on recent advances in applied virus research, the use of
yeast as a tool for antiviral drug development and as a vac-
cine vehicle, respectively.
1. Functional analysis of individual viral proteins in yeast
Although the expression of viral proteins in yeast not
always necessarily reflects their role in higher eukaryotes,
here we selected some examples in which the analysis in
yeast of their effect on highly conserved cellular processes
such as cell cycle control, apoptosis or mRNA degradation
have contributed to the current understanding of the
pathogenesis of important viral pathogens such as HIV-1
and HCV.
Human immunodeficiency virus
With around 40 million people infected worldwide and
no effective vaccine or curative therapy, HIV remains a
major human thread. A better understanding of the HIV
replication cycle and the viral and host factors involved
are essential to develop new therapy options. Yeast-based
studies have brought to light key aspects of the function of
three HIV proteins, the viral protein R (Vpr), the protease
(PR) and the regulatory viral protein (Rev). The Vpr pro-
tein plays a pivotal role in the pathogenesis of HIV-1. It is
involved in the suppression of immune functions and the
depletion of infected CD4+ T cells, which finally leads to
the progression to AIDS [20]. However, the mechanism
underlying its effects on pathogenesis was unknown.
Observations initially made in yeast and then corrobo-
rated in mammalian cells demonstrated that Vpr acts as
an inducer of G2 arrest and CD4+ T cell killing by induc-
tion of mitochondrial-dependent apoptosis [21]. The HIV
protease is needed to cleave the precursor Pr55Gag to the
mature proteins matrix (p17), capsid (p24), nucleocapsid
(p7) and p6 proteins [22]. Studies in S. cerevisiae demon-
strated that the PR specifically arrested cell growth and
induced cell lysis mediated by the loss of membrane
integrity [23]. The contribution of HIV-1 PR to HIV-
induced necrosis was later confirmed with a CD4+ human
T cell line, where a PR-specific inhibitor led to prevention
of virus-induced cell lysis [24]. These results highlight the
importance of PR-inhibitors to prevent CD4+ T cell loss
during infection. Finally, the Rev protein plays an essen-
tial role in the HIV replication cycle. Rev mediates the
export of unspliced and incompletely spliced HIV mRNAs
to the cytoplasm and thus, enables the production of HIV-
1 particles. The important finding showing that the Rev
protein mediates the export of HIV pre-mRNA by interact-
ing with it via cis-acting Rev responsive elements (RRE) in
the context of the spliceosome was first shown in yeast
[25]. These observations led to the identification in S. cer-
evisiae of the small-nucleoporin-like protein Rip1p as the
responsible cellular component for Rev-mediated export
[26] and of the Crm1p protein which mediates the inter-
action between Rip1p and Rev [27].
Hepatitis C virus
HCV has chronically infected more than 170 million peo-
ple worldwide and is a major cause of liver cirrhosis and
hepatocarcinoma. In spite of the great advances accom-
plished since its identification in 1989, there are still lim-
ited therapy options and no vaccine. The expression in S.
cerevisiae of two HCV proteins, the non-structural protein
5a (NS5a) and the core protein, together with the con-
struction of HCV chimeras to study HCV RNA translation
have made yeast a valuable tool in HCV research. In yeastMicrobial Cell Factories 2007, 6:32 http://www.microbialcellfactories.com/content/6/1/32
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and human cells, the NS5a protein predominantly associ-
ates with the ER membrane through the highly conserved
amphiphatic alpha-helix in its N-terminus [28,29]. This is
consistent with its proposed role as a key regulator for
membrane-associated viral replication. Moreover, studies
in yeast and human cells showed that N-terminally trun-
cated NS5a mutants were transported to the nucleus due
to a functional NLS and exhibited trans-activating proper-
ties [29-32]. Interestingly, the caspase-mediated cleavage
of NS5a, occurring during apoptosis or after interaction of
NS5a with the core protein during infection, resulted in
similar truncations which translocated to the nucleus [33-
35]. However, in which way the NS5a-dependent transac-
tivation contributes to HCV pathogenesis still remains to
be elucidated.
The HCV core protein interacts with NS5a and is linked to
many processes in HCV pathology. From mammalian
studies it is known that the HCV core protein influences
the transcription of cellular and viral promotors [36],
however the mechanisms involved were mainly
unknown. Studies in yeast demonstrated the effect of the
core protein on the transcription factor AP1-like. The core
protein is processed in yeast as in mammalian cells and
localizes in the nucleus and the cytoplasm [37-40]. The
transport of the mature core protein to the nucleus was
shown to be mediated by direct interaction with the
ortholog of human importin 4 (Kap123). This interaction
in turn abrogates the transport of the AP1-like transcrip-
tion factor (YAP-1) into the nucleus [37,41] and conse-
quently contributes to the regulation of transcription by
the core protein.
A bicistronic vector has been recently designed to study
HCV RNA translation in yeast [42]. The HCV RNA is not
capped and thus translation depends on an internal ribos-
omal entry site (IRES) located at the 5'non-translated
region (NTR). HCV IRES-mediated translation is modified
by the 3'-NTR and several viral and probably also host
proteins bind to the 5'-NTR of HCV [43]. Since HCV IRES
is functional in yeast [44,45] the bicistronic construct gen-
erated will allow to fully explore the effect of viral and cel-
lular factors on HCV translation.
2. Replication of higher eukaryotic viruses in yeast
An understanding of the fundamental steps of virus life
cycles including virus-host interactions is essential for the
design of novel effective antiviral strategies. Such under-
standing has been hampered by the complexity of higher
eukaryotic host organisms. To overcome these experimen-
tal difficulties, systems have been developed that allow
the replication of higher eukaryotic viruses in S. cerevisiae.
The first higher eukaryotic virus shown to replicate and
encapsidate its genome in S. cerevisiae was the Bromo
mosaic virus (BMV), a positive strand RNA ((+)RNA) virus
from plants [46,47]. This pioneer work opened new ave-
nues in virus research and allowed to apply the versatile
yeast genetic tools in the elucidation of fundamental steps
in virus replication. The list of higher eukaryotic viruses
shown to replicate in yeast has been expanded ever since
and include (i) other viruses with RNA genomes that
infect plants (Carnation Italian Ringspot virus (CIRV),
Tomato Bushy Stunt virus (TBSV) and Cymbidium Ringspot
virus (CymRSV)) or animals (Flock House virus (FHV) and
Nodamura virus (NoV)), and (ii) viruses with DNA
genomes that infect humans (Human papillomavirus), ani-
mals (Bovine papillomavirus) or plants (Mungbean Yellow
Mosaic India Virus (MYMIV)) [48-53]. Importantly, these
yeast systems reproduce the known features of virus repli-
cation in their corresponding natural hosts. Since a
detailed description of each of these systems and contri-
butions has been recently reviewed [54,55], we will only
highlight some main achievements in virus research. In
particular, we will focus on studies carried out with yeast/
RNA virus systems since they are the most advanced.
All RNA viruses that have been shown to replicate in yeast
belong to the group of (+)RNA viruses. This large virus
group includes many important plant, animal and human
pathogens such as HCV and the severe acute respiratory syn-
drome coronavirus (SARS). All (+)RNA viruses share com-
mon features in their replication cycles. First, the genomic
RNA serves as messenger RNA (mRNA) for translation of
the viral proteins and as template for replication. Since
these two functions are mutually exclusive, the transfer of
the genomic RNA from the cellular translation machinery
to the replication complex must be highly regulated. Sec-
ond, viral replication complexes are associated with intra-
cellular host membranes which proliferate and rearrange
in response to the expression of viral protein. And third,
host factors are required at multiple steps of the viral rep-
lication cycle [56-58].
All the yeast/(+)RNA virus systems developed show com-
mon characteristics. (i) the viral RNA-dependent RNA
polymerase (RdRp) and additional proteins required for
viral replication are expressed in trans from yeast plas-
mids, (ii) the genomic RNA with authentic 5' and 3' ends
is also transcribed from a yeast plasmid or transfected
directly into the cell, and (iii) replication is monitored by
detecting viral RNA via Northern blot analysis or by meas-
uring the expression of a reporter gene inserted into the
viral genome, such that its expression depends on viral
RNA replication. The fact that in these systems the individ-
ual viral proteins are given in trans from separate plasmids
is of great advantage since it allows simplifying and con-
trolling functional studies of each player on viral replica-
tion. With this, important aspects of the viral life cycles
were studied like translation of viral proteins, the process
of template selection, formation of the replication com-Microbial Cell Factories 2007, 6:32 http://www.microbialcellfactories.com/content/6/1/32
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plex, viral RNA replication, encapsidation and recombina-
tion (reviewed in detailed in [54,55,59]. These studies
have resulted in an impressive progress in the understand-
ing of these fundamental steps of viral RNA replication
and the viral proteins involved. Furthermore, due to the
common replication strategy of (+)RNA viruses, the
results obtained go much beyond the specific virus stud-
ied.
The identification of the host factors involved in viral RNA
replication is a priority area of research in virology
because it can provide new targets for antiviral drug devel-
opment. The use of traditional yeast genetics and genome-
wide screenings have resulted in the groundbreaking iden-
tification of multiple host factors required for viral RNA
replication and recombination. The gene-deletion mutant
collection in which all the non-essential yeast genes are
deleted was used to carry out genome-wide screenings of
host factors affecting the replication of BMV and TBSV
[60,61]. In the BMV studies each of the single deletion
strains was transformed with plasmids expressing the
BMV replicases (the polymerase 2a and the helicase 1a)
and a BMV RNA replication template harbouring a luci-
ferase reporter gene which expression was screened as a
marker for BMV RNA replication. In the TBSV studies, a
similar approach was applied; however, effects on replica-
tion were followed by direct visualization in ethidium-
bromide-stained gels of a shorter form of the TBSV RNA,
which accumulates at a very high level in the wild-type
strain. These analyses revealed that from the approxi-
mately 5000 non-essential yeast genes analyzed, around
100 were found to affect the replication of each virus.
These results uncovered the involvement in viral replica-
tion of previously unconsidered cellular pathways, such as
mRNA turnover, stress response and the ubiquitin path-
way of protein degradation. Surprisingly and against all
previous predictions, only 4 genes were found to be com-
mon in both studies. This was discussed to be possibly
related to the fact that BMV and TBSV replicate in associa-
tion with cellular membranes from different compart-
ments.
In spite of the impressive achievement in identifying
essential host facors for replication, the above mentioned
approach has the limitation that only the non-essential
genes can be screened. To overcome this, an additional
genome-wide screening was performed in the yeast Tet
promoter Hughes collection (yTHC) with TBSV [62]. In
the yTHC, which covers 800 of the ~1000 essential genes,
each essential gene is under the control of a tet-titratable
promoter in the genome [9]. In this way, the expression of
the essential gene can be turned off by the addition of dox-
ycycline to the yeast growth medium. With this approach
30 additional cellular genes were identified that are
involved in the replication of TBSV [62].
TBSV not only replicates in yeast but also undergoes
recombination [49]. To elucidate the eventual role of host
factors in the viral RNA recombination process, genome-
wide screenings were performed in both yeast collections
mentioned above [63,64]. Since the recombinant and
non-recombinant TBSV forms vary in length, a screening
was performed by direct visualization of TBSV RNA in aga-
rose gels in combination with Northern blot analysis and
RT-PCR sequencing. The genetic screens identified 11
nonessential and 16 essential genes that affected TBSV
recombination. The exciting observation that host factors
can influence viral RNA recombination and thereby evo-
lution has brought a totally new perspective to the field.
3. Yeast as a tool for antiviral drug development
Major viral pathogens still remain without effective vac-
cine or therapy options, thus safer and more effective anti-
viral drugs are urgently needed. For this, improved
screening processes that enable to assess the mode-of-
action of the tested compounds are essential. In this sec-
tion we will discuss the exciting contributions of yeast
genetics and high-throughput screenings to drug develop-
ment. We will present first the principal characteristics of
these global approaches and then their application to the
antiviral research field.
The process that leads to the discovery and development
of new drugs is long and costly. Two approaches have
been traditionally used. If the target is already known, the
drug discovery search classically starts with in vitro assays
to identify small molecule inhibitors. These assays give
only a partial view of the effect of the compounds since,
for instance, they cannot fully explore drug effects on
other additional targets, which can be the source of unde-
sirable side effects. Putative toxic effects will be tested sub-
sequently in cell culture and in animal models. However,
if toxicity is detected, the underlying mechanism will still
be unknown and no rational approach is possible to mod-
ify the drug to improve safety.
An alternative drug discovery approach directly performs
cell-based screens for molecules that produce a specific
desired effect. This has the advantage that the molecule
encounters natural physiological conditions and allows
selecting those molecules that are stable within the meta-
bolic environment and discarding those that show toxic
effects. However, also with this approach the exact mech-
anism of action of the selected drug remains unknown.
This is a great disadvantage, since its elucidation could
lead to the design of new compounds with improved
safety and efficacy profiles. Both above approaches will
benefit from the large-scale chemical and genetic tools
developed in S. cerevisiae that allow to systematically
screen putative targets and effects of the selected drugs
[17,19]. Since the effect of a drug on every yeast gene isMicrobial Cell Factories 2007, 6:32 http://www.microbialcellfactories.com/content/6/1/32
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analyzed, a broad view of all the proteins and related met-
abolic pathways affected can be accomplished. Thus,
including yeast-based screenings at an early stage in drug
development programmes, crucial information will be
rapidly obtained that can be used to discard or to improve
the tested compounds.
The large-scale chemical and genetic yeast screens use the
mutant strain collections and gene expression plasmids
described above. There are five main screening
approaches [19]. First, the drug-induced haploinsuffi-
ciency approach uses the heterozygous mutant collection
and is based on the finding that reducing the copy
number of a drug target gene from two to one copy can
significantly sensitize a diploid cell to that drug [65-67].
The second approach uses the haploid or the homozygous
diploid deletion collection and is based on the principle
that the deletion of a gene that renders cell-hypersensitiv-
ity to a specific drug identifies pathways that buffer the
cell against the toxic effect of the drug and thus provides
clues about its mode of action [68,69]. The third approach
uses gene expression libraries and is based on the princi-
ple that increasing the concentration of a protein that is
the target of an inhibitory drug should increase resistance
to the drug. These three approaches can be performed in
two different ways, (i) by growth measurement of arrayed
strains, and (ii) by competitively growing pooled strains.
The fourth approach is based on gene expression profiling
and consists of comparing changes in mRNA expression
elicited by a drug of interest with those induced by other
drugs or by gene deletions. Finally, the plasmid collection
of all yeast proteins expressed as GST-fusions was used to
create protein chips that allow the screening of direct
drug-protein interactions. The combination of all the five
powerful techniques together with the rapidly growing
knowledge of yeast genetic networks[70] has made yeast a
recognized system in drug development that until today
has not been fully exploited in antiviral research.
After more than two decades of searching for antiviral
drugs, a rather limited number of compounds is on the
market. From these, almost all focus on HIV and Herpesvi-
ruses. Furthermore, most antivirals are not curative and
produce major side effects. Thus, there is an urgent need
of novel and high-quality targets and drugs together with
improved screening systems to identify them. Two kinds
of targets can be used in antiviral research, viral factors or
host factors. Classically, viral proteins have been used as
targets for therapeutic interventions because the devel-
oped inhibitor molecules were expected not to produce
significant side effects. However, this does not seem to be
the case and, for instance, all the antiretrovirals currently
available produce important side effects. Since drug-resist-
ant mutants are rather easily selected, researchers have
shown again interest in host factors. They have the advan-
tage of being genetically stable and may even be efficient
as targets against groups of viruses. The above mentioned
screening options could be helpful to select those host fac-
tors that when targeted by drugs will be lethal for the virus
but have minor effects on the cell.
Two yeast cell-based assays have been established to
screen for viral inhibitors. The protein M2 of influenza
virus has a fundamental role in the disassembly of the
influenza virion. In fact, some of the commercially avail-
able drugs target this protein.
Since expression of the M2 protein in yeast produced a
slower growth rate, a screening procedure was set up
based on the rescue of wt cell growth in the presence of
test compounds [71]. More recently, a parallel approach
has been applied to the serine protease encoded by the
human cytomegalovirus (HCMV) [72]. This protease is
essential for the virus and recognizes a 40 amino acid
sequence, which was inserted into the coding sequence of
a yeast enzyme involved in the biosynthesis of tryp-
tophan. Coexpression of the HCVM protease with the
engineered enzyme resulted in an arrest of cell growth in
media without tryptophan that could be rescued in the
presence of protease inhibitors. This system provides the
basis for the high-throughput screening of inhibitory mol-
ecules. Related to the analysis of host factors as antiviral
targets, the genome-wide screenings in the yeast/virus sys-
tems described in the previous section have provided
many new candidates for which the therapeutic potential
remains to be explored.
Few studies in antiviral research make fully use of the
yeast platforms and tools available. Because of their inno-
vation in the field, we would like to point out two of them
that explore the mode of action of antivirals plus other
therapeutic compounds. In the first study the heterozy-
gote yeast deletion collection was used to asses the cellular
effects of 78 different compounds [67]. It is important to
mention that in the construction of this collection, each
yeast gene was replaced with a cassette containing the
selectable marker gene KanMx  plus two unique tag
sequences located up- and down-stream of the marker
gene. These tag sequences enabled rapid analysis of strains
in a pool by using hybridization to high-density nucle-
otide arrays. Importantly, the tag sequences were flanked
with universal primer sets for polymerase chain reaction
amplification [8]. Thus, a pool of ~3500 heterozygous
deletion strains were competitively grown for 20 genera-
tion in media containing the selected compounds. Then,
DNA was extracted from the cell culture at generation 0
and 20 and amplified by PCR using universal primers and
Cy3 (green) or Cy5 (red) labels, respectively. The ampli-
fied DNA was hybridized to microarrays containing each
specific tag sequence. Since signal intensities from micro-Microbial Cell Factories 2007, 6:32 http://www.microbialcellfactories.com/content/6/1/32
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array hybridizations are proportional to the relative tag
abundance in the pool population, for each yeast strains
red, green or yellow colours in the array will correlate with
an enrichment, depletion or unchanged representation of
the strain in the population. In this way the effect of a drug
on each of the yeast deletion strains could be rapidly ana-
lyzed [67].
In a second study a complementary approach was fol-
lowed. The ~5000 yeast haploid deletion mutant collec-
tion was tested for hypersensitivity to 82 different
compounds including some molecules with antiviral
activity [69]. Since it is considered that compounds with
similar biological effects lead to similar chemical profiles,
clustering of the obtained results provided a very useful
data set that allowed the organization of the compounds
into functionally relevant groups. The results obtained
with both studies helped to identify new modes of action
of the tested compounds and revealed numerous insights
into the cellular pathways involved,
4. Yeast as a vaccine vehicle
Yeast has been utilized in vaccine development. The clas-
sical example is the recombinantly expressed hepatitis B
surface antigen that has become a safe and efficient pro-
phylactic vaccine worldwide [73]. However, in this sec-
tion we will focus on its use not as a mere production tool
for recombinant antigens but as a vaccine vehicle itself.
Immunization against bacterial pathogens and viruses is
an attractive strategy in combating infectious diseases by
stimulation of the immune system. Traditional vaccines
like soluble antigens formulated with adjuvants efficiently
activate the humoral immune response. The production
of neutralizing antibodies that bind to invading microor-
ganisms inhibits their entry into target cells, thereby pre-
venting an infection. However, cell-mediated immunity,
not humoral immunity alone, is required to control infec-
tions with intracellular pathogens, especially viruses like
HIV and HCV. In the classical view of cellular immunity,
antigen-presenting cells (APC) present peptides from
endogenously synthesized pathogen proteins in the con-
text with MHC class I molecules on their cell surface. Anti-
gen-specific CD8-positive T lymphocytes become
activated by recognizing these peptides and subsequently
differentiate into a mature effector cell population. These
cytotoxic T cells (CTL) are able to recognize and kill the
respective infected cells. Additionally, dendritic cells (DC)
which are the most potent APC use the mechanism of
cross-priming for antigen presentation, wherein peptides
from exogenous antigens are also presented via MHC class
I molecules [74]. "Danger" signals as given by the interac-
tion of pathogen components (e.g. cell wall components
of yeast) with pattern recognition receptors on the surface
of APC, such as Toll-like receptors (TLR), mannose or glu-
can receptors, leading to the maturation of the APC and
an efficient antigen presentation [75,76].
Whole recombinant yeast cells, known as Tarmogens™
(targeted molecular immunogens) represent a novel vac-
cination tool for the induction of potent cell-mediated
immune responses against target antigens [77]. In most
cases, the non-pathogenic baker's yeast Saccharomyces cer-
evisiae has been used as antigen carrier because this genus
combines several advantages. (1) Products with S. cerevi-
siae, e.g. bread and beer, are consumed in large amounts
worldwide and healthy individuals show only moderate T
cell responses against S. cerevisiae, probably due to mech-
anisms of oral tolerance [78]. (2) Important for prime-
boost immunization strategies is the observation that
there is no neutralization of yeast vectors by the host
immune system following multiple immunizations in
mice and rabbits [79,80]. Remarkable low titres of anti-
yeast antibodies were found after repeated injections of
either live or heat-killed antigen-expressing S. cerevisiae
[77]. (3) Yeast cells themselves have potent adjuvant
effect via "danger" signals that lead to the maturation of
DC without being dangerous, so no exogenous adjuvant
is needed [80,81]. (4) Facilitated by the particulate struc-
ture of yeast, antigens are efficiently presented via the
MHC class I pathway resulting in the activation of anti-
gen-specific CD8 T lymphocytes [81-83].
Stubbs et al. showed for the first time that recombinant
yeasts expressing HIV-1 antigens and tumour antigens
potently elicit antigen-specific CTL responses, including
those mediating tumour protections in mice [80]. Further
studies with the animal tumour challenge model could
demonstrate that yeast-based immunotherapy using
mutated Ras oncoprotein as target antigen caused a
mutant-selective tumour remission in animals [77,79].
This concept is now being tested in a Phase I clinical trial
in patients with colorectal, pancreatic and non-small cell
lung cancers [77]. Most recently, the same group has eval-
uated a recombinant yeast cell vaccine that expresses the
HCV NS3-Core fusion protein as an immunotherapeutic
vaccine in chronic HCV-infected individuals [84].
One advantage of using whole recombinant yeasts as anti-
gen carriers is the oral application route. Feeding mice
with S. cerevisiae expressing Actinobacillus pleuropneumo-
niae antigen led to the induction of protective systemic
and mucosal immune responses [85]. The fission yeast
Schizosaccharomyces pombe represents, like S. cerevisiae, a
physiologically and genetically well characterized eukary-
ote that has been used in Africa for hundreds of years in
brewing of millet beer, from which it was first isolated.
Recombinant  Sz. pombe cells expressing the human
cytomegalovirus pp65 protein were able to stimulateMicrobial Cell Factories 2007, 6:32 http://www.microbialcellfactories.com/content/6/1/32
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CD4- and CD8-positive memory T cells in human blood
[82].
Instead of using recombinant yeast expressing an antigen
of choice as a vaccine, attempts have been made to express
MHC proteins plus the desired antigenic peptide on the
yeast surface and to use the modified cell as a kind of APC.
Brophy and colleagues succeeded in expressing mouse
MHC I protein heavy chain, beta2-microglobulin plus an
antigenic peptide from a single gene cassette. The resulting
complex assembled in a functional conformation on the
cell surface and even induced the activation of naïve T
cells [86]. However whether this approach will be of prac-
tical use in vaccination has yet to be demonstrated.
The strategy to use yeast cells for vaccination could also be
used to elicit protective immune responses against human
pathogenic yeasts. For example, the genus Candida is able
to cause a variety of infections from mucosal candidiasis
to life-threatening disseminated and bloodstream infec-
tions, especially in immunocompromised individuals.
Unfortunately, the interplay between protective and
inhibitory antibodies dictates the outcome of experimen-
tally disseminated Candidiasis in mice receiving a heat-
inactivated whole-cell C. albicans vaccine [87]. This obser-
vation may explain why subjects with elevated anti-Cand-
ida  antibody titers remain nonetheless susceptible to
invasive candidiasis [87]. However, Ibrahim and col-
leagues could show that vaccination with the recom-
binant N-terminal domain of the adhesin Als1p improves
survival during murine disseminated candidiasis by
enhancing cell-mediated, not humoral, immunity in
both, immunocompetent and immunocompromised
mice [88,89].
Conclusion
In conclusion, the yeast system has been extremely valua-
ble in virus research. However, the full potential from the
remarkable progress in systemic yeast biology over the last
years has yet to be exploited. With the increasing options
for analysing protein interaction networks at an unprece-
dented level of complexity and the rising number of viral
replication systems in yeast that correctly mimic the fun-
damental properties of the virus life cycle in higher
eukaryots, the era of system virology is expected to
become a new focus in virus research. Subsequently, the
better understanding of the virus protein/host cell protein
interaction networks will allow the search for and devel-
opment of more efficient and safer antiviral drugs. More-
over, the acquired information about drug functioning
down to the molecular level will help in the search for
new drug applications and might significantly reduce the
time frame for drug development when a new virus
appears to threaten the human population.
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